Antoine Angelergues

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Venues

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, Marie-Ange Mouret-Reynier, Olfa Derbel, Elsa Kalbacher, Marianne LeHeurteur, Alejandra Martinez, Corina Cornila, Mathilde Martinez, Leila Bengrine Lefevre, Frank Priou, Nicolas Cloarec, Laurence Venat, Frédéric Selle, Dominique Berton-Rigaud, Olivier Collard, Elodie Coquan, Olivia Le Saux, Isabelle Treilleux, Sophie Gouerant, Antoine Angelergues, Florence Joly, Olivier Tredan
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. Nature communications 15 (1) (2024)
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, Marie-Ange Mouret-Reynier, Olfa Derbel, Elsa Kalbacher, Marianne LeHeurteur, Alejandra Martinez, Corina Cornila, Mathilde Martinez, Leila Bengrine Lefevre, Frank Priou, Nicolas Cloarec, Laurence Venat, Frédéric Selle, Dominique Berton-Rigaud, Olivier Collard, Elodie Coquan, Olivia Le Saux, Isabelle Treilleux, Sophie Gouerant, Antoine Angelergues, Florence Joly, Olivier Tredan
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. Nature communications 15 (1) (2024)
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, Marie-Ange Mouret-Reynier, Olfa Derbel, Elsa Kalbacher, Marianne LeHeurteur, Alejandra Martinez, Corina Cornila, Mathilde Martinez, Leila Bengrine Lefevre, Frank Priou, Nicolas Cloarec, Laurence Venat, Frédéric Selle, Dominique Berton-Rigaud, Olivier Collard, Elodie Coquan, Olivia Le Saux, Isabelle Treilleux, Sophie Gouerant, Antoine Angelergues, Florence Joly, Olivier Tredan
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. Nature communications 15 (1) (2024)
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, Marie-Ange Mouret-Reynier, Olfa Derbel, Elsa Kalbacher, Marianne LeHeurteur, Alejandra Martinez, Corina Cornila, Mathilde Martinez, Leila Bengrine Lefevre, Frank Priou, Nicolas Cloarec, Laurence Venat, Frédéric Selle, Dominique Berton-Rigaud, Olivier Collard, Elodie Coquan, Olivia Le Saux, Isabelle Treilleux, Sophie Gouerant, Antoine Angelergues, Florence Joly, Olivier Tredan
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. Nature communications 15 (1) (2024)

Antoine Angelergues.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Antoine Angelergues